Alvotech And DKSH Partner On Adalimumab In Asia
After Deals In Canada, Europe And Israel, Alvotech Targets Asia
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.
You may also be interested in...
Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.
Alvogen’s central and eastern European business, which started up in 2010, has now been sold to the Zentiva group. Zentiva plans to combine both companies’ branded generics and OTC businesses in the CEE region.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context